At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 45 enrolled
Drug / intervention
Dasiglucagon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo
In Brief
A Phase 3 clinical trial evaluating Dasiglucagon and Placebo for Hypoglycemia and Diabetes Mellitus, Type 1. Completed, enrolled 45 participants across 3 sites.
Detailed Summary
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycemia, Diabetes Mellitus, Type 1
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 2018
Enrollment StartNov 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedSep 28, 2018
Enrollment StartNov 1, 2018
Primary CompletionMar 11, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.8 years ago
Interventions
Dasiglucagondrug
Glucagon analogue
Placebodrug
Placebo for dasiglucagon